Peculiarities of tuberculosis in the COVID‑19 pandemic

L. D.  Todoriko; I. O.  Semianiv

doi:10.32902/2663-0338-2020-3-27-34

L. D. Todoriko Higher State Educational Establishment of Ukraine “Bukovinian State Medical University”, Chernivtsi https://orcid.org/0000-0001-9042-0073
I. O. Semianiv Higher State Educational Establishment of Ukraine “Bukovinian State Medical University”, Chernivtsi https://orcid.org/0000-0003-0340-0766

DOI: https://doi.org/10.32902/2663-0338-2020-3-27-34

Abstract

OBJECTIVE. The purpose of our comprehensive analysis is to assess the prospects for the effects of the interaction between coronavirus disease 2019 (COVID‑19) and tuberculosis (TB) and to strategize the risks of spreading TB infection in a coronavirus pandemic.

MATERIALS AND METHODS. Test access to full-text and abstract databases was used.

RESULTS AND DISCUSSION. An analysis of the available literature has shown that a 3-month lockdown and a long 10-month recovery worldwide could lead to an additional 6.3 million TB cases and another 1.4 million TB deaths between 2020 and 2025. On average, the detection of TB in Ukraine decreased by 27.4 %, and the incidence of TB among children decreased by 34.5 %. This is an alarming figure because we know very well that within 6 months the number of patients with TB has not decreased, they simply stopped being detected. In addition, COVID‑19 may accelerate the activation of latent TB infection and thus increase the number of active cases.

CONCLUSIONS. The overall incidence of TB in 2021 will increase to the level that was last observed between 2013 and 2016. The epidemiological indicators of TB control are expected to deteriorate for at least 5-8 years due to the COVID‑19 pandemic. Long-term results can be strongly affected by the rate of short-term recovery. Priority should be given to all governments, during a pandemic, to ensure the continuity of basic health care, including the implementation of national TB programs.

Keywords: tuberculosis, COVID‑19, epidemiology, pandemic.

References

Bhimraj A., Morgan R., Shumaker A. et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID‑19. Available at: https://www.idsociety.org/practiceguideline/covid‑19-guideline-treatment-and-management.

Brodin P. Why is COVID‑19 so mild in children? Acta Paediatr. 2020; 109: 1082-1083. https://doi.org/10.1111/apa.15271.

Castagnoli R., Votto M., Licari A. et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV‑2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatr. 2020. Available at: https://jamanetwork.com/journals/jamapediatrics/fullarticle/2765169.

Gandhi R., Lynch J., Del Rio C. Mild or moderate COVID‑19. N. Engl. J. Med. 2020. doi: 10.1056/NEJMcp2009249.

Guan W. J., Ni Z. Y., Hu Y. et al. China Medical Treatment Expert Group for COVID‑19. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020; 382 (18): 1708-1720. doi: 10.1056/NEJMoa2002032.

He X., Lau E. H.Y., Wu P. et al. Temporal dynamics in viral shedding and transmissibility of COVID‑19. Nat. Med. 2020; 26 (5): 672-675. doi: 10.1038/s41591-020-0869-5.

Kincaid E. COVID‑19 Daily: HCQ Hospital Protocols, ED Physician Death. Medscape. 2020. Available at: https://www. medscape.com/viewarticle/929383.

Lavezzo E., Franchin E., Ciavarella C. et al. Suppression of COVID‑19 outbreak in the municipality of Vo, Italy. medRxiv. 2020. doi: 10.1101/2020.04.17.20053157.

Li X., Geng M., Peng Y. et al. Molecular immune pathogenesis and diagnosis of COVID‑19. J. Pharm. Anal. 2020; 10 (2): 102-108. doi: 10.1016/j.jpha.2020.03.001.

McIntosh K. Coronavirus disease 2019 (COVID‑19): epidemiology, virology, clinical features, diagnosis, and prevention. Available at: https://www.uptodate.com/contents/coronavirusdisease‑2019-covid‑19-epidemiology-virology-clinical-featuresdiagnosis-and-prevention.

Pathak L., Gayan S., Pal B. et al. (2020). Coronavirus activates a stem cell mediated defense mechanism that accelerates activation of dormant tuberculosis: implications for the COVID‑19 pandemic. bioRxiv preprint. doi: https://doi.org/10.1101/2020.05.06.077883.

Tadolini M., Codecasa L., Garcia-Garcia Je-Mia et al. Active tuberculosis, sequelae and COVID‑19 co-infection: first cohort of 49 cases. Eur. Respir. J. 2020. DOI: 10.1183/13993003.01398-2020.

Togun T., Kampmann B., Stoker N. et al. Anticipating the impact of the COVID‑19 pandemic on TB patients and TB control programmes. Annals of Clinical Microbiology and Antimicrobials. 2020; 19: 21. DOI: 10.1186/s12941-020-00363-1.

Wong H. Y.F., Lam H. Y.S., Fong A. H. et al. Frequency and distribution of chest radiographic findings in COVID‑19 positive patients. Radiology. 2020: 201160. doi: 10.1148/radiol.2020201160.

World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID‑19-11 May 2020. Available at: https://www.who.int/dg/speeches/detail/who-directorgeneral-s-opening-remarks-atthe-media-briefing-on-covid‑19-11-may‑2020.

World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. 2020. Available at: https://www.who.int/publications-detail/laboratory-testingfor‑2019-novel-coronavirusin-suspected-human-cases20200117.

Wu C., Chen X., Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020. doi: 10.1001/jamainternmed.2020.0994.

Zhang T., Wu Q., Zhang Z. Probable pangolin origin of SARS-CoV‑2 associated with the COVID‑19 outbreak. Curr. Biol. 2020; 30 (7): 1346-1351. doi: 10.1016/j.cub.2020.03.022.

Zheng J. SARS-CoV‑2: an emerging coronavirus that causes a global threat. Int. J. Biol. Sci. 2020; 16 (10): 1678-1685. doi: 10.7150/ijbs.45053.

Zhu N., Zhang D., Wang W. et al. A novel coronavirus from patients with pneumonia in China. N. Engl. J. Med. 2020; 382: 727-733. doi: 10.1056/NEJMoa2001017.

Zumla A., Niederman M. The explosive epidemic outbreak of novel coronavirus disease 2019 (COVID‑19) and the persistent threat of respiratory tract infectious diseases to global health security. Curr. Opin. Pulm. Med. 2020. doi: 10.1097/MCP.0000000000000676.

Available at: https://www.news-medical.net/news/20200510/COVID‑19-could-accelerate-activation-of-dormant-tuberculosis-(TB).aspx.

Available at: http://www.stoptb.org/covid19maps.asp.

Available at: https://ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-020-00363-1.

Available at: https://erj.ersjournals.com/content/early/2020/05/13/13993003.01398-2020.article-info.

Available at: https://www.who.int/news-room/commentaries/detail/bacille-calmette-gu%C3%A9rin-(bcg)-vaccination-and-covid‑19.

Available at: https://www.who.int/docs/default-source/documents/tuberculosis/infonote-tb-covid‑19.%20onset.

Available at: https://www.who.int/teams/global-tuberculosis-programme/covid‑19.

Available at: https://www.who.int/news-room/q-a-detail/tuberculosis-and-the-covid‑19-pandemic#.

Available at: https://www.theunion.org/news-centre/news/covid‑19-and-tuberculosisthreats-and-opportunities.

Available at: https://www.sciencedirect.com/science/article/pii/S2531043720301033.